Edition:
United States

Auris Medical Holding AG (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Global Market

0.86USD
24 Jul 2017
Change (% chg)

-- (--)
Prev Close
$0.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
64,070
52-wk High
$5.44
52-wk Low
$0.60

Latest Key Developments (Source: Significant Developments)

Auris Medical completes enrollment of phase 3 healos trial of am-111 for the treatment of sudden deafness
Wednesday, 5 Jul 2017 08:01am EDT 

July 5 (Reuters) - Auris Medical Holding AG ::Auris Medical completes enrollment of phase 3 healos trial of am-111 for the treatment of sudden deafness.Auris Medical Holding AG - ‍top-line results from healos trial are expected in fall of 2017.​.Says ‍auris Medical expects to announce top-line results from assent trial in second half of 2018​.Auris Medical Holding AG - ‍primary efficacy endpoint for trial is improvement of pure tone hearing thresholds from baseline to day 28​.  Full Article

Auris Medical reports Q1 loss per share chf 0.22
Thursday, 11 May 2017 06:16am EDT 

May 11 (Reuters) - Auris Medical Holding Ag : :Auris Medical provides business update and reports first quarter 2017 financial results.Q1 loss per share chf 0.22.Auris Medical Holding AG - net loss for q1 of 2017 was chf 8.4 million, or chf 0.22 per share.Auris Medical Holding AG - continues to expect that its operating expenses in 2017 will be in range of chf 28 to 32 million.Auris Medical Holding AG - continues to expect existing cash and cash equivalents will enable funding of operations into q1 of 2018.  Full Article

Auris Medical reports key results from Keyzilen Ampact2 open-label extension study
Monday, 24 Apr 2017 08:01am EDT 

April 24 (Reuters) - Auris Medical Holding Ag :Auris medical reports key results from Keyzilen Ampact2 open-label extension study.Trial outcomes show positive safety profile of Keyzilen for chronic intermittent use.Exploratory efficacy results support therapeutic concept of early tinnitus treatment.Says trial outcomes show positive safety profile of Keyzilen for chronic intermittent use.Says auris medical expects to announce results from ampact1, open-label extension study related to TACTT2, later this quarter.TACTT3 extended to recruit additional 60 patients in each of stratum A and B, enrollment ongoing; top-line results expected in early 2018.As recruitment for Ampact2 has completed, open-label extension is not offered to patients currently enrolling in extended TACTT3 trial.  Full Article

Auris Medical Holding files for mixed shelf of up to $100 mln
Friday, 14 Apr 2017 09:53am EDT 

Auris Medical Holding Ag : Files for mixed shelf of up to $100 million - sec filing .In addition, selling shareholder may offer up to 241,117 common shares.  Full Article

Auris Medical expects 2017 operating expenses will be in range of chf 28 to 32 mln
Tuesday, 14 Mar 2017 06:01am EDT 

Auris Medical Holding Ag : Auris medical provides business update and reports full year 2016 financial results . Auris medical holding ag- expects that its operating expenses in 2017 will be in range of chf 28.0 to 32.0 million .Auris medical holding ag says with proceeds from february 2017 offering, company's cash runway has been extended into q1 of 2018.  Full Article

Auris Medical expands clinical development pipeline for vertigo treatment
Friday, 3 Feb 2017 06:31am EST 

Auris Medical Holding Ag : Auris Medical expands clinical development pipeline with intranasal betahistine for the treatment of meniere's disease and vestibular vertigo . Auris Medical Holding Ag - under product code am-125, to develop betahistine dihydrochloride in spray formulation . Auris Medical Holding Ag - entered into an agreement with otifex therapeutics pty. ltd. To purchase various assets related to intranasal betahistine .Auris Medical Holding Ag - plans to initiate a second phase 1 trial for intranasal betahistine in 2017.  Full Article

Auris Medical resumes enrollment in tactt3 phase 3 trial of Keyzilen
Thursday, 26 Jan 2017 08:04am EST 

Auris Medical Holding AG : Auris Medical resumes enrollment in tactt3 phase 3 trial of keyzilen in acute and post-acute tinnitus . Auris Medical Holding - amended protocol elevates tinnitus functional index score from a key secondary endpoint to an alternate primary efficacy endpoint . Auris Medical Holding AG - "we look forward to top-line results in early 2018" . Auris Medical Holding AG says amended protocol increases trial size with enrollment of an additional 60 patients in each of stratum A and B .Auris Medical Holding AG - amended protocol includes certain patient subgroups in confirmatory statistical testing.  Full Article

Auris Medical on track to resume enrollment of keyzilen tinnitus program
Tuesday, 6 Dec 2016 07:04am EST 

Auris Medical Holding AG: Auris Medical on track to resume enrollment of keyzilen tinnitus program following regulatory feedback . Auris Medical Holding AG - "we look forward to top-line results from tactt3's trial in early 2018" . Auris Medical Holding AG - through type c meeting, FDA confirmed , as per standard practice, 2 positive confirmatory trials would be required to submit NDA .Auris Medical Holding AG - in separate FDA meeting , alignment was achieved on key items of keyzilenchemistry, manufacturing, controls section for future NDA.  Full Article

Auris reports top-line results from TACTT2 trial with Keyzilen
Thursday, 18 Aug 2016 07:30am EDT 

Auris Medical Holding AG : Reports top-line results from TACTT2 trial with Keyzilen in acute inner ear tinnitus . Treatment with Keyzilen did not demonstrate statistically significant difference in tinnitus improvement versus placebo . TACTT2 trial did not meet its co-primary efficacy endpoints . Top-Line results from the phase 3 TACTT3 trial expected in the fourth quarter of 2016 . Keyzilen was well tolerated with no drug-related serious adverse events Further company coverage: [EARS.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Auris medical Q2 loss per share CHF 0.25
Thursday, 18 Aug 2016 07:21am EDT 

Auris Medical Holding AG : Auris Medical provides business update and reports second quarter 2016 financial results . Q2 loss per share CHF 0.25 . Continues to expect that its operating expenses in 2016 will be in range of CHF 33.0 to 38.0 million .Existing cash and cash equivalents, including $12.5 million loan, will enable funding of operations until year-end 2017.  Full Article

BRIEF-Auris Medical Holding completes acquisition of various assets

* Auris Medical Holding- announced that it has completed its acquisition of various assets related to intranasal betahistine from Otifex Therapeutics